Zobrazeno 1 - 10
of 69
pro vyhledávání: '"Matt Shirley"'
Autor:
Simon Fung, Matt Shirley
Publikováno v:
CNS Drugs. 37:363-370
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b7ffa7ee61e3c67020c82a7758186073
https://doi.org/10.1007/s40263-023-00995-9
https://doi.org/10.1007/s40263-023-00995-9
Autor:
Matt Shirley
Publikováno v:
Targeted Oncology. 18:295-302
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ebc45ed2d4829526f49b70bca6d10e7a
https://doi.org/10.1007/s11523-022-00944-4
https://doi.org/10.1007/s11523-022-00944-4
Autor:
Matt Shirley
Publikováno v:
Drugs & Therapy Perspectives. 38:508-519
The adrenal cytotoxic agent mitotane (Lysodren®) has a central role in the systemic treatment of adrenocortical carcinoma (ACC), a rare and aggressive cancer of the adrenal glands. Although its precise mechanism of action remains unclear, mitotane h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a037d4086ceb3b6f745cce417ea1c70
https://doi.org/10.1007/s40267-022-00958-y
https://doi.org/10.1007/s40267-022-00958-y
Autor:
Matt Shirley
Publikováno v:
Targeted Oncology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::79081209f1d693ff6c8d2d9923e3fc25
https://doi.org/10.1007/s11523-023-00977-3
https://doi.org/10.1007/s11523-023-00977-3
Autor:
Matt Shirley
Publikováno v:
Drugs & Therapy Perspectives.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::36976161fa5aa3145083c87eebc99c6f
https://doi.org/10.1007/s40267-023-00997-z
https://doi.org/10.1007/s40267-023-00997-z
Autor:
Matt, Shirley
Publikováno v:
Drugs. 82:989-999
The introduction of multi-valent pneumococcal vaccines around the world, such as the 13-valent pneumococcal conjugate vaccine (PCV13), has had a significant effect in reducing the burden of disease caused by Streptococcus pneumoniae infection globall
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c0de818a08e203a38ff84c964a14302
https://doi.org/10.1007/s40265-022-01733-z
https://doi.org/10.1007/s40265-022-01733-z
Autor:
Matt Shirley, Susan J. Keam
Publikováno v:
Drugs. 82:577-584
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b47ca61e2af77d89cc54c570e3bcd7b5
https://doi.org/10.1007/s40265-022-01695-2
https://doi.org/10.1007/s40265-022-01695-2
Autor:
Matt Shirley
Publikováno v:
Targeted Oncology
Starting with the first-in-class agent ibrutinib, the development of Bruton tyrosine kinase (BTK) inhibitors has led to dramatic improvements in the management of B-cell malignancies. Subsequently, more-highly selective second-generation BTK inhibito
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7a23029c06c4d12358342fee51d6489
http://europepmc.org/articles/PMC8783859
http://europepmc.org/articles/PMC8783859
Autor:
Matt Shirley
Publikováno v:
Drugs
Maralixibat (Livmarli™) is an orally-administered, small-molecule ileal bile acid transporter (IBAT) inhibitor being developed by Mirum Pharmaceuticals for the treatment of rare cholestatic liver diseases including Alagille syndrome (ALGS), progres
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1507c03ccd55542e5a8d09d00ae03ef
http://europepmc.org/articles/PMC8748361
http://europepmc.org/articles/PMC8748361
Autor:
Matt Shirley
Publikováno v:
Drugs & Therapy Perspectives. 37:347-353
The second-generation (atypical) antipsychotic lurasidone (Latuda®) presents a useful option to consider for the treatment of schizophrenia in adolescents. As demonstrated in a 6-week, randomised, double-blind, placebo-controlled phase 3 clinical tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::921fa103eac87f001b4ef9e5ccb5074f
https://doi.org/10.1007/s40267-021-00849-8
https://doi.org/10.1007/s40267-021-00849-8